{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"62.0"},{"groupId":"OG003","value":"28.6"},{"groupId":"OG004","value":"28.6"},{"groupId":"OG005","value":"20.7"},{"groupId":"OG006","value":"13.8"},{"groupId":"OG007","value":"25.8"},{"groupId":"OG008","value":"0.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"58"},{"groupId":"OG006","value":"29"},{"groupId":"OG007","value":"31"},{"groupId":"OG008","value":"33"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants having a complete response (CR) or partial response (PR) as determined by investigator assessment of radiographic disease per RECIST v1.1. CR per RECIST v 1.1 was defined as disappearance of all target lesions. PR per RECIST v 1.1 was defined as At least a 30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the Baseline sum diameters. Data is reported as per dose received by the participants with a particular cancer type. CR per Cheson criteria was defined as complete disappearance of all detectable clinical evidence of disease and disease-related symptoms. PR per Cheson criteria was defined as at least a 50% decrease in sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses.","groups":[{"description":"Participants with Colorectal Cancer received epacadostat 100 mg BID in combination with nivolumab 240 mg IV infusion Q2W on Days 1, 15, 29, and 43 of each 8-week cycle.","id":"OG000","title":"Phase 2: Epacadostat 100 mg + Nivolumab 240 in Colorectal Cancer"},{"description":"Participants with DLBCL received epacadostat 300 mg BID in combination with nivolumab 240 mg IV infusion Q2W on Days 1, 15, 29, and 43 of each 8-week cycle.","id":"OG001","title":"Phase 2: Epacadostat 300 mg + Nivolumab 240 mg in DLBCL"},{"description":"Participants with Melanoma(I/O Naive) received epacadostat 100 mg or 300 mg BID in combination with nivolumab 240 mg IV infusion Q2W on Days 1, 15, 29, and 43 of each 8-week cycle.","id":"OG002","title":"Phase 2: Epacadostat 100/300 mg + Nivolumab 240 mg in Melanoma(I/O Naive)"},{"description":"Participants with Melanoma (I/O Relapsed) received epacadostat 100 mg BID in combination with nivolumab 480 mg IV infusion Q2W on Days 1, 15, 29, and 43 of each 8-week cycle.","id":"OG003","title":"Phase 2 Epacadostat 100mg + Nivolumab 480 mg in Melanoma (I/O Relapsed)"},{"description":"Participants with Melanoma (I/O Refractory) received epacadostat 100 mg BID in combination with nivolumab 480 mg IV infusion Q2W on Days 1, 15, 29, and 43 of each 8-week cycle.","id":"OG004","title":"Phase 2 Epacadostat 100mg + Nivolumab 480 mg in Melanoma (I/O Refractory)"},{"description":"Participants with NSCLC received epacadostat 100 mg or 300 mg BID in combination with nivolumab 240 mg IV infusion Q2W on Days 1, 15, 29, and 43 of each 8-week cycle.","id":"OG005","title":"Phase 2 Epacadostat 100/300 mg + Nivolumab 240 mg in NSCLC"},{"description":"Participants with Ovarian Cancer received epacadostat 100 mg or 300 mg BID in combination with nivolumab 240 mg IV infusion Q2W on Days 1, 15, 29, and 43 of each 8-week cycle.","id":"OG006","title":"Phase 2 Epacadostat 100/300 mg + Nivolumab 240 mg in Ovarian Cancer"},{"description":"Participants with SCCHN received epacadostat 100/300 mg BID in combination with nivolumab 240 mg IV infusion Q2W on Days 1, 15, 29, and 43 of each 8-week cycle.","id":"OG007","title":"Phase 2 Epacadostat 100/300 mg + Nivolumab 240 mg in SCCHN"},{"description":"Participants with Glioblastoma received epacadostat 100/300 mg BID in combination with nivolumab 240 mg IV infusion Q2W on Days 1, 15, 29, and 43 of each 8-week cycle.","id":"OG008","title":"Phase 2 Epacadostat 100/300 mg + Nivolumab 240 mg in Glioblastoma"}],"paramType":"NUMBER","populationDescription":"The Phase 2 Full Analysis Population includes all participants enrolled in the study who received at least 1 dose of study drug. The data is reported per cancer type in this outcome measure.","reportingStatus":"POSTED","timeFrame":"From first dose up end of the study (up to approximately 6 years)","title":"Phase 2: Objective Response Rate (ORR) in Participants With Select Solid Tumors Per Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1 for Participants With Solid Tumors and Per Cheson Criteria for Participants With DLBCL","type":"PRIMARY","unitOfMeasure":"percentage of participants"}